Albany, NY -- (SBWire) -- 05/02/2018 --Drug reconstitution can be a challenging task for non-professionals managing a chronic illness. The dosage forms should ideally be easy to administer, safe, and cost-effective. However, in order to ensure chemical and physical stability of the product, most drugs are formulated in the lyophilized form to be reconstituted at the time of administration. The lyophilized form maintains drug stability and efficacy during the shelf-life period and reduces the time required to make products stable in liquid dosage forms. This enables rapid entry of a new drug into the market, maintaining the market competitiveness. Reconstitution and mixing was a tedious job earlier; however, technological advancements have resulted in the development of novel drug reconstitution systems, making the reconstitution process easier with minimum dosing errors. These systems are highly preferred by patients, as they are well-engineered to reduce their efforts and help them stick to the dosage regimen. Selecting the right reconstitution alternative depends upon the type of drug, the diluent volume type, the administration method, and overfill issues.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39269

Growing research and development activities by pharmaceutical and biopharmaceutical vendors, rising prevalence of several chronic diseases, increasing health care expenditure worldwide, and benefits of novel drug reconstitution systems are factors driving the global novel drug reconstitution systems market. Reconstitution systems offer several advantages such as ease of administration, reduced drug loss, decreased need for overfilling by manufacturers, improved safety, and better patient compliance. Moreover, increasing inclination toward self-administration of drugs and increasing trend of development of patient-centric drug delivery systems by manufacturers are expected to boost the global novel drug reconstitution systems market during the forecast period. However, increased costs of products led by introduction of novel techniques and stringent regulatory requirements are factors restraining the global novel drug reconstitution systems market.

The global novel drug reconstitution systems market can be segmented based on product, distribution channel, and region. In terms of product, the market can be categorized into vial adaptors, vial-to-vial systems, needleless transfer devices, direct connection to vial devices, and dual chamber syringes. Vial adapters are quick, safe, and cost-effective. They improve the reconstitution performance. A vial adapter contains a syringe with or without diluent filled in it and a vial containing lyophilized drug. The vial-to-vial system comes with an adapter connecting two vials. This is an attractive type of novel drug reconstitution system, as it does not require needles. The direct connection to vial devices enables manufacturers to design a compact packaging for the product. In terms of distribution channel, the global novel drug reconstitution systems market can be segmented into hospital pharmacy, retail pharmacy, and e-commerce system. The retail pharmacy segment is expected to hold the maximum market share by the end of the forecast period. The e-commerce segment is anticipated to expand at the maximum CAGR during the forecast period.

Request a discount of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39269

Geographically, the global novel drug reconstitution systems market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global novel drug reconstitution systems market, owing to growing incidence of chronic diseases, high adoption of technologically advanced products in the region, high health care expenditure, and growing R&D activities to develop novel products to enhance patient comfort by players in the U.S. Europe is the second-largest market for novel drug reconstitution systems, due to growing geriatric population, increasing investments in R&D activities, and rising adoption of novel drug delivery systems to treat chronic conditions. Asia Pacific is considered as an emerging market for novel drug reconstitution systems, owing to presence of developing economies, increasing health care expenditure, and constantly rising population in the region.

Key players operating in the global novel drug reconstitution systems market are West Pharmaceutical Services, Inc., Integrity Bio, Inc., Sensile Medical AG, Yukon Medical, Nemera, Credence MedSystems, Inc., Alkermes, and Baxter.

View Report @ https://www.transparencymarketresearch.com/novel-drug-reconstitution-systems-market.html